Semax Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Semax evidence and protocol review

Neuro Research peptide LyophilizedLiquid verified

Also known as: ACTH(4-7)PGP

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 mg, 10 mg, 20 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Catalog Description

Semax is a synthetic heptapeptide analog of ACTH(4-7), developed at the Institute of Molecular Genetics, Russian Academy of Sciences. It is approved in Russia (intranasal) for stroke, cognitive disorders, and optic nerve disease, and was added to Russia's List of Vital and Essential Drugs in 2011. Proposed mechanisms include BDNF and NGF upregulation via the CREB signaling pathway and dopaminergic sensitization. The strongest supporting data are Russian-language clinical studies; neither Semax nor Selank has been evaluated in a randomized controlled trial under Western regulatory standards, and independent replication is limited.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

No robust independently replicated clinical half-life suitable for a universal RUO schedule

Onset

Acute CNS effects reported within minutes to hours of intranasal dosing in Russian studies

Administration Routes (Research)

Intranasal in the cited human and animal studies

Reported Research Effects

BDNF/NGF upregulation via CREB pathway (proposed mechanism)
Approved in Russia for stroke and cognitive-disorder indications (intranasal)
Dopaminergic sensitization (proposed mechanism)

Reported Research Side Effects

Human safety reporting in English-language abstracts is incomplete
Intranasal irritation and formulation contamination are possible
Regional product concentration and indication must be verified
Animal findings do not establish human benefit

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

6000 mcg/day intranasally for 10 days, a 20-day interval, then a second 10-day course at 6000 mcg/day [Intranasal; Human ischemic-stroke rehabilitation study; Daily during two courses]Source: PMID 29798983
Intranasal Semax for 6 days after experimental cortical ischemia [Intranasal; Rat focal-ischemia model; Daily study course, dose not extractable from abstract]Source: PMID 17603664

Research Notes

The human protocol is now captured exactly as two 10-day, 6000 mcg/day courses. The earlier translated psoriasis abstract that rendered 0.1% Semax as 600 mg/day was excluded as an unsafe likely unit or translation error.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Semax ischemic-stroke rehabilitation clinical study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/29798983/

Semax experimental cortical-ischemia study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/17603664/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.